AntiCoagAF vs Biosimilar

This application is for medical practitioners who need to quickly review which anticoagulant (including the direct oral anticoagulants (DOACs)) to use to prevent stroke in patients with non-valvular atrial fibrillation (NVAF). It contains relevant information about warfarin, apixaban, dabigatran, rivaroxaban and edoxaban. Topics covered include: comparison of anticoagulants, patient information, when anticoagulation is required, risk-benefit issues, when warfarin is appropriate, how to choose the dose of a DOAC, starting or switching between anticoagulants, edoxban information, clinical monitoring, bleeding risks, use of antiplatelet agents in addition to oral anticoagulants, managing ischemic strokes on DOACs, reversing anticoagulation in the event of intracerebral haemorrhage, a Cookcroft-Gault creatinine clearance calculator and peri-operative management information. Information contained within the application was edited by Dr Bruce Campbell. Coding was by CereScape (www.cerescape.com). It is our aim to keep this information current, and we welcome constructive comments and evidenced updated information. Any profit generated by this application will be used to fund stroke research.

Biologic drugs offer important treatment options for patients suffering from auto-immune disorders such as rheumatoid arthritis and for common cancers including breast and colon. Biosimilar and interchangeable products, which can loosely be thought of as ‘generic’ biologics, are important for promoting competition and driving down costs. The FDA maintains a list of approved biosimilars in the Purple Book. The Biosimilar iOS app provides a handy reference to the Purple Book as well as important information related to prescribing and dispensing for clinicians and pharmacists navigating this complex area of drug therapeutics. ** Disclaimer ** - non-medical users should ask for a doctor’s advice in addition to using this app and before making any medical decisions.